Investigational Hepatitis D Monoclonal Antibody Achieves 100% Virologic Response
The monoclonal antibody’s manufacturer, Bluejay Therapeutics, also reports in its phase 2 clinical trial there was up to a78% combined virologic response and ALT normalization as monotherapy.